Baxter International Past Earnings Performance
Past criteria checks 2/6
Baxter International's earnings have been declining at an average annual rate of -43.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 5.9% per year. Baxter International's return on equity is 1.6%, and it has net margins of 0.8%.
Key information
-43.3%
Earnings growth rate
-43.1%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 5.9% |
| Return on equity | 1.6% |
| Net Margin | 0.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?
Sep 05
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Revenue & Expenses Breakdown
How Baxter International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15,062 | 121 | 3,540 | 653 |
| 30 Jun 24 | 14,962 | 98 | 3,487 | 653 |
| 31 Mar 24 | 14,892 | -38 | 3,512 | 658 |
| 31 Dec 23 | 14,813 | -76 | 3,495 | 655 |
| 30 Sep 23 | 11,379 | 96 | 2,907 | 537 |
| 30 Jun 23 | 12,389 | -2,932 | 3,103 | 555 |
| 31 Mar 23 | 14,461 | -2,673 | 3,489 | 608 |
| 31 Dec 22 | 14,506 | -2,666 | 3,550 | 599 |
| 30 Sep 22 | 14,275 | -2,568 | 3,435 | 580 |
| 30 Jun 22 | 13,892 | 876 | 3,212 | 562 |
| 31 Mar 22 | 13,396 | 992 | 2,957 | 553 |
| 31 Dec 21 | 12,146 | 1,022 | 2,605 | 530 |
| 30 Sep 21 | 12,451 | 1,214 | 2,530 | 528 |
| 30 Jun 21 | 12,197 | 1,120 | 2,460 | 521 |
| 31 Mar 21 | 11,817 | 1,068 | 2,370 | 499 |
| 31 Dec 20 | 11,673 | 1,102 | 2,405 | 519 |
| 30 Sep 20 | 11,531 | 911 | 2,360 | 516 |
| 30 Jun 20 | 11,410 | 924 | 2,383 | 528 |
| 31 Mar 20 | 11,526 | 991 | 2,414 | 552 |
| 31 Dec 19 | 11,362 | 1,001 | 2,442 | 561 |
| 30 Sep 19 | 11,156 | 1,335 | 2,348 | 554 |
| 30 Jun 19 | 11,066 | 1,484 | 2,359 | 573 |
| 31 Mar 19 | 11,060 | 1,505 | 2,399 | 595 |
| 31 Dec 18 | 11,099 | 1,552 | 2,401 | 618 |
| 30 Sep 18 | 11,063 | 1,065 | 2,527 | 636 |
| 30 Jun 18 | 11,009 | 795 | 2,572 | 632 |
| 31 Mar 18 | 10,763 | 840 | 2,478 | 621 |
| 31 Dec 17 | 10,584 | 609 | 2,516 | 615 |
| 30 Sep 17 | 10,432 | 1,025 | 2,424 | 584 |
| 30 Jun 17 | 10,283 | 904 | 2,382 | 564 |
| 31 Mar 17 | 10,263 | 1,852 | 2,447 | 560 |
| 31 Dec 16 | 10,163 | 4,966 | 2,520 | 566 |
| 30 Sep 16 | 10,121 | 4,909 | 2,566 | 573 |
| 30 Jun 16 | 10,050 | 4,784 | 2,625 | 584 |
| 31 Mar 16 | 9,940 | 3,646 | 2,704 | 582 |
| 31 Dec 15 | 9,968 | 393 | 2,832 | 589 |
| 30 Sep 15 | 10,154 | 337 | 2,972 | 585 |
| 30 Jun 15 | 10,376 | 510 | 3,087 | 593 |
| 31 Mar 15 | 9,274 | 84 | 3,037 | 473 |
| 31 Dec 14 | 10,719 | 457 | 3,182 | 608 |
| 30 Sep 14 | 12,252 | 739 | 3,301 | 743 |
| 30 Jun 14 | 13,253 | 1,092 | 3,334 | 847 |
| 31 Mar 14 | 15,367 | 1,967 | 3,437 | 1,047 |
| 31 Dec 13 | 9,413 | 315 | 2,859 | 534 |
Quality Earnings: BAX has a large one-off loss of $1.0B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: BAX's current net profit margins (0.8%) are lower than last year (0.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAX's earnings have declined by 43.3% per year over the past 5 years.
Accelerating Growth: BAX's earnings growth over the past year (26%) exceeds its 5-year average (-43.3% per year).
Earnings vs Industry: BAX earnings growth over the past year (26%) exceeded the Medical Equipment industry 10.4%.
Return on Equity
High ROE: BAX's Return on Equity (1.6%) is considered low.